These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 25424050)

  • 1. Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis.
    Mazur M; Karczewski J; Lodyga M; Żaba R; Adamski Z
    J Dermatolog Treat; 2015; 26(4):326-8. PubMed ID: 25424050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
    Schafer P
    Biochem Pharmacol; 2012 Jun; 83(12):1583-90. PubMed ID: 22257911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
    Gan EY; Chong WS; Tey HL
    BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apremilast for the treatment of psoriatic arthritis.
    Souto A; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
    Elyoussfi S; Thomas BJ; Ciurtin C
    Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New targets in psoriatic arthritis.
    Braun J
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii30-ii37. PubMed ID: 27856658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apremilast in psoriatic arthritis.
    Schett G
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S98-100. PubMed ID: 26472278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M; Papp K
    BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs for psoriatic arthritis.
    Caso F; Del Puente A; Peluso R; Caso P; Girolimetto N; Del Puente A; Scarpa R; Costa L
    Expert Opin Emerg Drugs; 2016; 21(1):69-79. PubMed ID: 26807876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of Psoriasis Arthritis Taking into Account New Treatment Options].
    Ryser C; Ciurea A
    Praxis (Bern 1994); 2018; 107(21):1147-1153. PubMed ID: 30326810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apremilast: first global approval.
    Poole RM; Ballantyne AD
    Drugs; 2014 May; 74(7):825-37. PubMed ID: 24797159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
    Pincelli C; Schafer PH; French LE; Augustin M; Krueger JG
    J Drugs Dermatol; 2018 Aug; 17(8):835-840. PubMed ID: 30124722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis.
    Fantuzzi F; Del Giglio M; Gisondi P; Girolomoni G
    Expert Opin Ther Targets; 2008 Sep; 12(9):1085-96. PubMed ID: 18694376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis.
    Victor FC; Gottlieb AB; Menter A
    Clin Dermatol; 2003; 21(5):392-7. PubMed ID: 14678719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apremilast in the treatment of psoriasis and psoriatic arthritis.
    Gooderham M; Papp K
    Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.
    Krueger G; Callis K
    Arch Dermatol; 2004 Feb; 140(2):218-25. PubMed ID: 14967799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.